Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methyldopa

FDA-approved product (tablet, oral), marketed as Aldomet, Methyldopa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Methyldopa
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hypertension

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Methyldopa
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA21.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae8.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methyldopa in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methyldopa with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • [18F]F-DOPA Imaging in Patients With Autonomic Failure

    NCT04246437 · start 2020-02-04

    Registered record
    Registry ID
    NCT04246437
    Conditions
    Autonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy; Dementia With Lewy Bodies
    Interventions
    [18F]FDOPA; Carbidopa 200mg oral dose; Entacapone 400mg oral dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2020-02-04
    Completion
    2027-02-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAutonomic Failure; Pure Autonomic Failure; Parkinson Disease; Multiple System Atrophy +1 more
    Intervention[18F]FDOPA; Carbidopa 200mg oral dose; Entacapone 400mg oral dose
    PhasePhase 1
    Registry statusRecruiting

  • Enhancement of Stroke Rehabilitation With Levodopa

    NCT03735901 · start 2019-06-14

    Registered record
    Registry ID
    NCT03735901
    Conditions
    Acute Stroke; Stroke Rehabilitation
    Interventions
    IMP Levodopa 100mg/Carbidopa 25mg; Matching placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2019-06-14
    Completion
    2029-06-30
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Stroke; Stroke Rehabilitation
    InterventionIMP Levodopa 100mg/Carbidopa 25mg; Matching placebo
    PhasePhase 3
    Registry statusActive not recruiting

  • L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

    NCT03761030 · start 2019-01-09

    Registered record
    Registry ID
    NCT03761030
    Conditions
    Major Depressive Disorder; Dysthymia; Depression
    Interventions
    L-DOPA; Placebo Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2019-01-09
    Completion
    2021-09-08
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder; Dysthymia; Depression
    InterventionL-DOPA; Placebo Oral Tablet
    PhasePhase 4
    Registry statusTerminated

  • Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations

    NCT03210025 · start 2017-09-20

    Registered record
    Registry ID
    NCT03210025
    Conditions
    Healthy
    Interventions
    BF-Methyldopa 250mg Tablet; Metopa Tab 250mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-20
    Completion
    2017-10-15
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBF-Methyldopa 250mg Tablet; Metopa Tab 250mg
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic of Levodopa Study in Healthy Males

    NCT03140956 · start 2017-04-19

    Registered record
    Registry ID
    NCT03140956
    Conditions
    Parkinson Disease
    Interventions
    Levodopa, carbidopa, ODM-104
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-19
    Completion
    2017-08-03
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionLevodopa, carbidopa, ODM-104
    PhasePhase 1
    Registry statusCompleted

  • Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

    NCT03115827 · start 2017-04-18

    Registered record
    Registry ID
    NCT03115827
    Conditions
    Parkinson Disease
    Interventions
    Droxidopa; Carbidopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-18
    Completion
    2018-12-21
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionDroxidopa; Carbidopa
    PhasePhase 4
    Registry statusCompleted

  • Dose-finding Pharmacokinetic Study in Healthy Males

    NCT03055936 · start 2017-02-21

    Registered record
    Registry ID
    NCT03055936
    Conditions
    Healthy Volunteers
    Interventions
    Levodopa; Carbidopa; ODM-104
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-02-21
    Completion
    2017-06-09
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLevodopa; Carbidopa; ODM-104
    PhasePhase 1
    Registry statusCompleted

  • A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

    NCT02799381 · start 2017-02-09

    Registered record
    Registry ID
    NCT02799381
    Conditions
    Parkinson's Disease (PD)
    Interventions
    Optimized antiparkinsonian treatment; Levodopa-Carbidopa Intestinal Gel (LCIG); CADD-Legacy ambulatory infusion pump; Percutaneous endoscopic gastrostomy tube; Jejunal extension tube
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-02-09
    Completion
    2019-09-19
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease (PD)
    InterventionOptimized antiparkinsonian treatment; Levodopa-Carbidopa Intestinal Gel (LCIG); CADD-Legacy ambulatory infusion pump; Percutaneous endoscopic gastrostomy tube +1 more
    PhasePhase 3
    Registry statusCompleted

  • Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy

    NCT01912677 · start 2015-04

    Registered record
    Registry ID
    NCT01912677
    Conditions
    Hypertension in Pregnancy; Preeclampsia
    Interventions
    Nifedipine; Labetalol; Methyldopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-04
    Completion
    2017-12
    Enrolment
    894

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension in Pregnancy; Preeclampsia
    InterventionNifedipine; Labetalol; Methyldopa
    PhasePhase 4
    Registry statusCompleted

  • Early Vascular Adjustments During Hypertensive Pregnancy

    NCT02531490 · start 2015-01-01

    Registered record
    Registry ID
    NCT02531490
    Conditions
    Hypertension, Pregnancy-Induced; Pre-Eclampsia
    Interventions
    Labetalol; Nifedipine; Methyldopa
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2015-01-01
    Completion
    2023-04
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Pregnancy-Induced; Pre-Eclampsia
    InterventionLabetalol; Nifedipine; Methyldopa
    PhasePhase 4
    Registry statusUnknown

  • Early Vascular Adjustments to Prevent Preeclampsia

    NCT04216706 · start 2014-11-01

    Registered record
    Registry ID
    NCT04216706
    Conditions
    Preeclampsia; Small for Gestational Age at Delivery; HELLP Syndrome
    Interventions
    tailored pharmaceutical treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-11-01
    Completion
    2020-03-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreeclampsia; Small for Gestational Age at Delivery; HELLP Syndrome
    Interventiontailored pharmaceutical treatment
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic Study in Healthy Males

    NCT02312232 · start 2014-11

    Registered record
    Registry ID
    NCT02312232
    Conditions
    Parkinson's Disease
    Interventions
    levodopa, carbidopa, ODM-104
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-11
    Completion
    2015-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease
    Interventionlevodopa, carbidopa, ODM-104
    PhasePhase 1
    Registry statusCompleted

  • Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes

    NCT01883804 · start 2013-06

    Registered record
    Registry ID
    NCT01883804
    Conditions
    Diabetes Mellitus, Type 1
    Interventions
    Methyldopa
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-06
    Completion
    2016-02
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 1
    InterventionMethyldopa
    PhaseNot applicable
    Registry statusCompleted

  • Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)

    NCT01770145 · start 2012-12

    Registered record
    Registry ID
    NCT01770145
    Conditions
    Parkinson's Disease; Motor Symptoms; Akinesia; Hypomobility; Delayed Levodopa Onset
    Interventions
    APOKYN; L-dopa; Trimethobenzamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-12
    Completion
    2014-04
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson's Disease; Motor Symptoms; Akinesia; Hypomobility +1 more
    InterventionAPOKYN; L-dopa; Trimethobenzamide
    PhasePhase 4
    Registry statusCompleted

  • Antipsychotic Augmentation With L-Dopa

    NCT01636037 · start 2012-09

    Registered record
    Registry ID
    NCT01636037
    Conditions
    Schizophrenia
    Interventions
    levodopa/carbidopa (generic version of Sinemet)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-09
    Completion
    2016-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionlevodopa/carbidopa (generic version of Sinemet)
    PhasePhase 2
    Registry statusCompleted